Navigation Links
Verenium Announces Signing of Lease for New Office and Lab Space
Date:6/29/2011

SAN DIEGO, June 29, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced the signing of a lease agreement for new office and laboratory space in the Torrey Pines area of San Diego, CA.  The lease is targeted to commence in the summer of 2012 following the build out of the new facility and the expiration of Verenium's current sublease, which was negotiated as part of the sale of its cellulosic biofuels business in July of 2010 to BP Biofuels North America.

"We are very excited to have identified a new location for Verenium that will accommodate our current and future growth," said James Levine, President and Chief Executive Officer at Verenium. "It was also important to us to remain in San Diego and we are particularly happy to be relocating to Torrey Pines, one of the area's most important centers for innovation which already houses some of the world's leading biotechnology companies and life sciences institutes.  We are pleased to be able to capitalize on a favorable real estate market and begin plans for building a customized space to support growing our business in the San Diego area."

About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward-Looking Statements for VereniumStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2010 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.Contacts For Verenium:Kelly Lindenboom

Vice President, Corporate Communications

858-431-8580

kelly.lindenboom@verenium.comSarah Carmody

Manager, Corporate Communications
858-431-8581

sarah.carmody@verenium.com
'/>"/>

SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes
2. Verenium Receives CLARUS Award at MDB Capitals Bright Lights Conference 2011
3. Verenium to Present at Upcoming Conferences
4. Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
5. Verenium to Present at MDB Capital Groups Bright Lights Conference
6. Verenium Announces Debt Repurchase
7. Worlds Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Vereniums Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval
8. Verenium Corporation to Announce Fourth Quarter and Year-End 2010 Financial Results
9. Verenium to Present at Jefferies 11th Global Clean Technology Conference
10. Verenium Announces Favorable Outcome of Capital Ventures International Lawsuit
11. Verenium to Present at Piper Jaffray Sixth Annual Clean Technology & Renewables Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , ... February 22, 2017 , ... ... is has acquired Kendall Research Systems, LLC (KRS) clinical development program. ... develops neural interface technology for research and clinical applications. The terms of the ...
(Date:2/22/2017)... 22, 2017  PrimeVax Immuno-Oncology, Inc. announced today its ... the Annual Biocom Global Life Science Partnering Conference.  The ... AM, at the Torrey Pines Lodge, in San Diego.  ... at Biocom who have chosen our company, amongst numerous ... companies, investors, and clinical researchers," said Mr. Chen. "In ...
(Date:2/22/2017)... (PRWEB) , ... February 22, ... ... Collaborative (TOPEC), the leading medical education provider of women’s health, primary ... by the Accreditation Council for Continuing Medical Education (ACCME). ACCME’s Accreditation with ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... engineers, and scientists from around the world, is pleased to announce the 2nd ... and 23, 2017. This premier, online-only conference focused on the development and advancements ...
Breaking Biology Technology:
(Date:2/7/2017)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the latest release ... flexible and award winning eClinical solution, is now available ... is a proven Software-as-a-Service (SaaS) clinical research technology platform ... also delivers an entire suite of eClinical tools to ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
Breaking Biology News(10 mins):